Company intelligence / Profile preview

SironRX Therapeutics

Cleveland, Ohio, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 1

Overview

JVS100 has been clinically tested in approximately 200 patients across multiple studies showing good safety and tolerability. The company was advancing into Phase II protocols focused on cosmetic surgical wounds with plans to submit protocols to regulatory authorities including FDA. The product aims to reduce scar formation and accelerate healing by recruiting endogenous stem cells via SDF‑1 expression.

Therapeutic areas: Dermatology
Modalities: Non-viral DNA plasmid therapy encoding a protein (JVS100 encodes SDF-1)Gene therapy-like modality using plasmid DNA to induce expression of stromal cell-derived factor 1
Industry: Biotech

Drug pipeline

1 asset

JVS-100

Phase 1

Indications: Dermal wound healing, Bone repair, Post-surgical wounds

Beyond the preview

Go deeper on SironRX Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SironRX Therapeutics.

Explore the full profile